Patient characteristics and clinical outcomes
| Targeted therapy-treated cohort, n=43 | Immunotherapy-treated cohort, n=32 | |
| Age, median (range) | 63.4 (33.6–80.4) | 63.0 (31.6–84.0) |
| Gender | ||
| Male | 32 (74%) | 25 (78%) |
| Female | 11 (26%) | 7 (22%) |
| Histology | ||
| Clear cell RCC | 34 (79%) | 26 (81%) |
| Non-clear cell RCC | 9 (21%) | 6 (19%) |
| Papillary RCC | 5 (12%) | 4 (13%) |
| Chromophobe RCC | 3 (7%) | 1 (3%) |
| Sarcomatoid RCC | 1 (2%) | 1 (3%) |
| Treatment | ||
| Sunitinib | 17 (40%) | – |
| Cabozantinib | 9 (21%) | – |
| Lenvatinib/everolimus | 6 (14%) | – |
| Pazopanib | 4 (9%) | – |
| Other targeted therapy | 7 (16%) | – |
| Nivolumab | – | 21 (66%) |
| Nivolumab/ipilimumab | – | 11 (34%) |
| Line of therapy | ||
| First-line | 33 (77%) | 11 (34%) |
| Second-line | 10 (23%) | 20 (63%) |
| Third-line | – | 1 (3%) |
| Best response | ||
| Complete response | 2 (5%) | 1 (3%) |
| Partial response | 7 (16%) | 6 (19%) |
| Stable disease | 28 (65%) | 12 (37%) |
| Progressive disease | 6 (14%) | 13 (41%) |
| Clinical benefit rate | 34 (79%) | 17 (53%) |
| Objective response rate | 9 (21%) | 7 (22%) |
| Median progression-free survival, months (95% CI) | 14.2 (95% CI 9.0 to 18.5) | 15.6 (95% CI Not Reached to Not Reached) |
IMDC, International Metastatic Renal Cell Carcinoma Consortium; N/A, not available; RCC, renal cell carcinoma.